IgG4相关病复发与新发器官受累的危险因素不同
该回顾性研究纳入86例IgG4相关病患者,中位随访63.1个月,分析复发器官受累(ROI)与新发器官受累(DNOI)的危险因素。多因素Cox分析显示,诊断时血嗜酸性粒细胞计数和持续糖皮质激素治疗与DNOI时间显著相关,而年龄和ANA阳性与ROI时间显著相关,提示两者危险因素不同,需采取不同预防策略。
要点
- ROI与DNOI的危险因素不同,需区分预防策略。
- 诊断时血嗜酸性粒细胞计数升高和未持续GC与DNOI风险相关。
- 年龄较低和ANA阳性与ROI风险相关。
核心结论
- IgG4相关病中复发器官受累(ROI)与新发器官受累(DNOI)的危险因素不同。
研究设计与样本
- 回顾性研究纳入86例IgG4相关病患者,采用单因素和多因素Cox回归分析ROI和DNOI相关因素。
主要发现
- 平均随访63.1个月,20例患者出现ROI(诊断后1.0-120个月),其中4例ROI时未用糖皮质激素(GC)。
- 15例患者出现DNOI(诊断后5.0-120个月),其中8例DNOI时未用GC。
- 多因素分析中,诊断时血嗜酸性粒细胞计数(每100/μl,HR 1.072,95%CI 1.018-1.129)和持续GC治疗(对比停药或观察不用GC,HR 0.245,95%CI 0.076-0.793)对DNOI时间有显著影响。
- 多因素分析中,年龄(HR 0.942,95%CI 0.899-0.986)和ANA阳性(对比阴性,HR 6.632,95%CI 1.892-23.255)对ROI时间有显著影响。
关键数值与推荐
- DNOI危险因素:诊断时血嗜酸性粒细胞计数每100/μl,HR 1.072(95%CI 1.018-1.129);持续GC对比停药或观察不用GC,HR 0.245(95%CI 0.076-0.793)。
- ROI危险因素:年龄,HR 0.942(95%CI 0.899-0.986);ANA阳性对比阴性,HR 6.632(95%CI 1.892-23.255)。
临床怎么用
- 对IgG4相关病患者,可根据诊断时血嗜酸性粒细胞计数、GC治疗状态、年龄和ANA状态区分ROI与DNOI风险,制定不同预防策略。
局限性
- 本研究为回顾性研究,样本量86例,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In IgG4-related disease (IgG4-RD), relapse including recurrent organ involvement (ROI) and de novo organ involvement (DNOI) occurs frequently during the clinical course. This study aimed to clarify the differences between the risk factors underlying ROI and DNOI in IgG4-RD. METHODS: We retrospectively investigated factors related to ROI and DNOI in 86 IgG4-RD patients. For assessment of factors related to ROI and DNOI, we performed uni- and multivariate Cox regression analyses. On stepwise multivariate analysis, we applied the variables with P < 0.1 in the univariate analysis and the predictors of relapse suggested in past reports. RESULTS: During the mean follow-up period of 63.1 months, ROI was detected at 1.0-120 months after diagnosis in 20 patients, 4 of whom were not receiving glucocorticoid (GC) at the time of ROI. In contrast, DNOI was detected at 5.0-120 months after diagnosis in 15 patients, 8 of whom were not receiving GC at the time of DNOI. In the multivariate analysis, blood eosinophil counts at diagnosis [per 100/μl; hazard ratio (HR) 1.072 (95% CI 1.018, 1.129)] and continuation of GC [vs discontinuation or observation without GC; HR 0.245 (95% CI 0.076, 0.793)] had a significant impact on the time to DNOI, whereas age [HR 0.942 (95% CI 0.899, 0.986)] and ANA positivity [vs negativity; HR 6.632 (95% CI 1.892, 23.255)] had a significant impact on the time to ROI. CONCLUSION: The present study suggests that the risk factors of ROI and DNOI are different in IgG4-RD, highlighting the need for different preventative strategies.
引用
- Mizushima I, Tsuge S, Fujisawa Y, et al. Different factors underlie recurrent and de novo organ involvement in immunoglobulin G4-related disease. Rheumatology (Oxford). 2020. PMID: 31373632. doi:10.1093/rheumatology/kez321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。